M. Kraus & Co Sells 708 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

M. Kraus & Co lowered its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,266 shares of the medical research company’s stock after selling 708 shares during the period. Thermo Fisher Scientific comprises about 5.7% of M. Kraus & Co’s portfolio, making the stock its 3rd largest holding. M. Kraus & Co’s holdings in Thermo Fisher Scientific were worth $19,340,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in TMO. Signature Resources Capital Management LLC increased its holdings in Thermo Fisher Scientific by 318.2% during the second quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company’s stock worth $25,000 after buying an additional 35 shares during the last quarter. New Millennium Group LLC bought a new stake in Thermo Fisher Scientific during the second quarter worth $29,000. Stephens Consulting LLC raised its position in Thermo Fisher Scientific by 116.0% during the second quarter. Stephens Consulting LLC now owns 54 shares of the medical research company’s stock worth $30,000 after acquiring an additional 29 shares in the last quarter. Headlands Technologies LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter valued at $32,000. Finally, Bank & Trust Co acquired a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $33,000. Institutional investors own 89.23% of the company’s stock.

Insider Activity

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 860 shares of the company’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $611.03, for a total value of $525,485.80. Following the transaction, the chief accounting officer now directly owns 1,814 shares in the company, valued at $1,108,408.42. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CAO Joseph R. Holmes sold 860 shares of the stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $611.03, for a total transaction of $525,485.80. Following the transaction, the chief accounting officer now directly owns 1,814 shares in the company, valued at approximately $1,108,408.42. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $76,420,473.36. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,084 shares of company stock valued at $14,094,292 in the last 90 days. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.7 %

Thermo Fisher Scientific stock traded up $3.88 during trading on Monday, hitting $600.80. 305,310 shares of the company were exchanged, compared to its average volume of 1,464,145. The business’s 50 day moving average is $607.73 and its 200 day moving average is $583.46. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $627.88. The company has a market capitalization of $229.51 billion, a P/E ratio of 37.09, a PEG ratio of 3.80 and a beta of 0.77. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.13 by $0.24. The business had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. Thermo Fisher Scientific’s revenue was down 1.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.15 earnings per share. Analysts predict that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Robert W. Baird raised their price target on Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Morgan Stanley lifted their target price on Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a report on Friday, September 20th. Raymond James raised their price target on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Redburn Atlantic assumed coverage on Thermo Fisher Scientific in a research report on Monday. They issued a “buy” rating and a $680.00 target price on the stock. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $767.00 target price on shares of Thermo Fisher Scientific in a research report on Friday, September 20th. Four equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $655.11.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.